BJMO - volume 12, issue 10, march 2018
A. de la Taille
Data regarding the natural history of prostate cancer (PCa) disease confirm the clinical insignificance of low-grade prostate cancer, which is associated with scant or no metastatic dissemination. Active surveillance (AS) is a conservative management approach, conducted for patients with “low-” or “favorable-risk” disease, which avoids long-term adverse effects on the patient’s quality of life. In a lecture during BMUC 2018, Prof. de la Taille explained why he thinks that AS is an option that we need to consider and why we should discuss this with the patient before the biopsy is taken.
BJMO - volume 12, issue 10, march 2018
Prof. P. Ost , PhD and Prof. B. Tombal
In a pro and con debate, Prof. Piet Ost and Prof. Betrand Tombal discussed the potential of metastasisdirected therapy for patients with oligorecurrent prostate cancer.
BJMO - volume 12, issue 10, march 2018
A. de la Taille
Over the last 10 years we have witnessed a revolution in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The introduction of several new therapeutic modalities had a significant impact on the overall survival (OS) of these patients. Whereas the median OS for patients with mCRPC was only 24.2 months back in 1997, this has increased to 39.4 months in a patient cohort from 2007 to 2013. This represents an increase in the median OS with 1.5 years.1 Currently, patients with mCRPC have 6 different drugs at their disposal. The question now is: “how to best sequence these different options?”
BJMO - volume 12, issue 10, march 2018
D. De Maeseneer MD, F.X. Otte MD, S. Albisinni MD
ASCO GU represents one of the yearly highlights in the field of genitourinary cancer. During BMUC 2018 the key data presented at this meeting were summarized.
BJMO - volume 12, issue 10, march 2018
Ronald de Wit; MD , PhD
The positive outcome of several randomized clinical trials evaluating immune checkpoint inhibitors in patients with metastatic bladder cancer dramatically changed the treatment paradigm in this setting. In his presentation, Prof. de Wit summarized the clinical data generated with PD-1/PD-L1 inhibitors in this setting, but he kicked off by summarizing the historical results obtained with chemotherapy in patients with metastatic urothelial cancer.
BJMO - volume 12, issue 10, march 2018
M. Kockx , MD , PhD
Immune checkpoint inhibition has rapidly changed the treatment paradigm of several cancer types, including non-small cell lung cancer (NSCLC), melanoma, urothelial cancer and renal cell carcinoma (RCC). Lots of research is currently focused on the search for biomarkers that can predict whether a patients will respond to immunotherapy or not. During his lecture at BMUC 2018, Dr. Mark Kockx, pathologist and founder of HistoGeneX shared his views on this matter.
BJMO - volume 12, issue 10, march 2018
L. Albiges
The introduction of immune checkpoint inhibitors dramatically changed the treatment paradigm of patients with advanced RCC. In her lecture, Dr. Laurence Albiges gave an overview of real-life data with nivolumab and gave her insights on how the first-line treatment landscape of patients with advanced RCC will evolve in the years to come.
Top
